该研究显示，伊尼妥单抗在HER2阳性晚期胃癌的一线治疗中，整体疗效与曲妥珠单抗相当。该项研究的结果已发表在World Journal of Gastroenterology 2024年刊上[2]。摘要号：158P 研究题目 Updated Efficacy and Safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric...
Hones A,Leyland- Jones B.Optimizing treatment of HER2 positive metastatic breast cancer.Seminars in Oncology. 2004Jones A, Leyland-Jones B. Optimizing treatment of HER2-positive metastatic breast cancer. Semin Oncol 2004; 31 (5 Suppl 10): 29-34....
[6]Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687...
8. Y.J. Bang, E. Van Cutsem, A. Feyereislova, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, ran...
12. S.Y. Rha, kun Lee C, H.S. Kim, et al. A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): molecular profiling and clinical update. J Clin...
[17]Trastuzumab deruxtecan (T-DXd) alone or in sequence with THP, versus standard treatment (ddAC-THP), in HER2-positive early breast cancer[EB/OL]. https://ClinicalTrials.gov/show/NCT05113251. [18]Ahn HK, Sim SH, Suh KJ, et ...
[21].Primary Analysis of a Phase 2 Single-Arm Trial of Trastuzumab Deruxtecan (T-DXd) in Western Patients With HER2-Positive (HER2+) Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Cancer Who Progressed on or After a Trastuzumab-containing Regimen.2021 ESMO. Abstract LBA55...
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
6.Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010 Aug 28;376(9742...
[3]Bang,Y.J.;Van Cutsem,E.;Feyereislova,A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial.Lancet(London,England)2010,376(9742)...